Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZD7OA)

Drug Name

Quaratusugene ozeplasmid Drug Info

Synonyms

GPX-001; CNVN 202

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Tumor suppressor candidate 2 (TUSC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fus-1 tumor suppressor gene therapy	DMXV6YP	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[3]
CNVN-202	DMWZOD7	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tumor suppressor candidate 2 (TUSC2)	TTJ8O14	TUSC2_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04486833) TUSC2-nanoparticles (GPX-001) and Osimertinib in Patients With Stage IV Lung Cancer Who Progressed on Osimertinib Alone. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Genprex.
3	INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201. Drugs R D. 2007;8(3):176-87.
4	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018766)